

February 6, 2025

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir / Madam,

**Sub: Unaudited Financial Results for the quarter and nine months period ended December 31, 2024.**

The Board of Directors of the Company at its meeting held today, February 6, 2025, has, inter alia, approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.

The aforesaid Un-audited Financial Results and Limited Review Report are also being updated on the website of the Company at <https://www.aurobindo.com/>

The Board meeting commenced at 4.30 p.m. and concluded at 6.45 p.m.

Please take the information on record.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Enclosures: as above

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

AUROBINDO PHARMA LIMITED  
(CIN - L24239TG1986PLC015190)  
[www.aurobindo.com](http://www.aurobindo.com)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India  
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024							
	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		Unaudited	Unaudited	Unaudited (refer note 5)	Unaudited	Unaudited (refer note 5)	Audited
<b>A</b>	<b>Continuing Operations:</b>						
1	<b>Revenue from operations</b>						
	(a) Net sales/ income from operations	28,835.6	27,578.8	26,638.7	80,666.6	76,758.1	1,05,422.1
	(b) Other operating income	330.7	667.1	281.6	1,346.5	758.0	1,034.3
	<b>Total revenue from operations</b>	<b>29,166.3</b>	<b>28,245.9</b>	<b>26,920.3</b>	<b>82,013.1</b>	<b>77,516.1</b>	<b>1,06,456.4</b>
2	<b>Other income</b>						
	(a) Foreign exchange gain (net)	-	714.0	556.7	679.7	938.8	942.6
	(b) Others	542.6	512.6	2,756.0	1,461.7	3,999.2	5,218.0
	<b>Total other income</b>	<b>542.6</b>	<b>1,226.6</b>	<b>3,312.7</b>	<b>2,141.4</b>	<b>4,938.0</b>	<b>6,160.6</b>
3	<b>Total income (1+2)</b>	<b>29,708.9</b>	<b>29,472.5</b>	<b>30,233.0</b>	<b>84,154.5</b>	<b>82,454.1</b>	<b>1,12,617.0</b>
4	<b>Expenses</b>						
	(a) Cost of materials consumed	15,065.9	14,247.4	14,659.3	42,495.1	43,595.2	57,610.8
	(b) Purchase of stock-in-trade	190.6	161.6	1,550.9	488.2	1,863.9	2,034.0
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(613.7)	(312.5)	(597.6)	(1,281.8)	(1,031.3)	(1,162.3)
	(d) Employee benefits expense	2,651.5	2,654.8	2,480.9	7,899.6	7,316.8	9,805.6
	(e) Finance costs	661.9	516.3	612.5	1,689.5	1,295.3	1,826.0
	(f) Foreign exchange loss (net)	281.0	-	-	-	-	-
	(g) Depreciation and amortisation expense	682.8	681.6	643.5	2,033.2	1,897.7	2,545.8
	(h) Other expenses	4,459.5	4,285.8	4,011.5	12,801.4	11,292.5	15,927.9
	<b>Total expenses</b>	<b>23,379.5</b>	<b>22,235.0</b>	<b>23,361.0</b>	<b>66,125.2</b>	<b>66,230.1</b>	<b>88,587.8</b>
5	<b>Profit before tax from continuing operations (3-4)</b>	<b>6,329.4</b>	<b>7,237.5</b>	<b>6,872.0</b>	<b>18,029.3</b>	<b>16,224.0</b>	<b>24,029.2</b>
6	<b>Tax expense</b>						
	Current tax	1,640.3	1,884.3	1,369.4	4,721.2	3,905.0	5,980.8
	Deferred tax	(31.4)	(22.1)	(735.1)	(78.1)	(888.1)	(952.6)
	<b>Total tax expense</b>	<b>1,608.9</b>	<b>1,862.2</b>	<b>634.3</b>	<b>4,643.1</b>	<b>3,016.9</b>	<b>5,028.2</b>
7	<b>Profit for the period from continuing operations (5-6)</b>	<b>4,720.5</b>	<b>5,375.3</b>	<b>6,237.7</b>	<b>13,386.2</b>	<b>13,207.1</b>	<b>19,001.0</b>
<b>B</b>	<b>Discontinued Operations: (Refer note 4)</b>						
8	Profit before tax from discontinued operations	-	-	-	-	724.9	724.9
9	Tax expense from discontinued operations	-	-	-	-	184.5	184.5
10	<b>Profit for the period from discontinued operations (8-9)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>540.4</b>	<b>540.4</b>
11	<b>Profit for the period (7+10)</b>	<b>4,720.5</b>	<b>5,375.3</b>	<b>6,237.7</b>	<b>13,386.2</b>	<b>13,747.5</b>	<b>19,541.4</b>
12	<b>Other comprehensive income</b>						
	Items that will not to be reclassified subsequently to profit or loss:						
	(a) Re-measurement of defined benefit liability	(19.4)	(33.2)	(3.9)	(58.2)	(17.8)	(22.6)
	(b) Income-tax relating to items that will not be reclassified to profit or loss	4.9	8.4	1.0	14.7	4.5	5.7
	<b>Other comprehensive loss for the period</b>	<b>(14.5)</b>	<b>(24.8)</b>	<b>(2.9)</b>	<b>(43.5)</b>	<b>(13.3)</b>	<b>(16.9)</b>
13	<b>Total comprehensive income for the period (11+12)</b>	<b>4,706.0</b>	<b>5,350.5</b>	<b>6,234.8</b>	<b>13,342.7</b>	<b>13,734.2</b>	<b>19,524.5</b>
14	Paid-up equity share capital (face value ₹ 1 per share) (Refer note 6)	580.8	580.8	585.9	580.8	585.9	585.9
15	Other equity						1,96,642.3
16	Earnings per equity share from continuing operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	8.13	9.21	10.65	22.94	22.54	32.43
	(b) Diluted (in ₹)	8.13	9.21	10.65	22.94	22.54	32.43
17	Earnings per equity share from discontinued operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	-	-	-	-	0.92	0.92
	(b) Diluted (in ₹)	-	-	-	-	0.92	0.92
18	Earnings per equity share for total operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	8.13	9.21	10.65	22.94	23.46	33.35
	(b) Diluted (in ₹)	8.13	9.21	10.65	22.94	23.46	33.35



Handwritten signature and date.



**NOTES:**

- 1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 6, 2025. The results for the quarter and nine months ended December 31, 2024 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2024.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 4 The Company transferred certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited) (APPL) on a going concern basis by way of slump sale with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.

**Key financials information of discontinued operations:**

₹ in million

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
Total Income	-	-	-	-	24,183.5	24,183.5
Total expenses	-	-	-	-	23,458.6	23,458.6
Profit before tax	-	-	-	-	724.9	724.9
Total tax expense	-	-	-	-	184.5	184.5
Net profit for the period	-	-	-	-	540.4	540.4

- 5 The Composite Scheme of Amalgamation under Sections 230 - 232 and other applicable provisions of the Companies Act, 2013 for amalgamation of Mviyes Pharma Ventures Private Limited ("Mviyes") and Auronext Pharma Private Limited ("Auronext") (together referred to as 'Amalgamating Companies') with the Company ('the Scheme') was sanctioned by Hon'ble National Company Law Tribunal (NCLT) Hyderabad bench vide order dated April 29, 2024. The Scheme has become effective on May 17, 2024 upon filing of the certified copy of the orders passed by NCLT with the relevant Registrar of Companies. In terms of the Scheme, all the assets, liabilities, reserves and surplus of the Amalgamating Companies have been transferred to and vested in the Company.


The amalgamation has been accounted under the 'pooling of interests' method in accordance with Appendix C of Indian Accounting Standard ('Ind AS') 103 'Business Combinations'. Accordingly, comparatives have been restated to give effect of the amalgamation in the previous year.

- 6 The Board of Directors at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the Company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations.

Consequently, the paid up equity share capital was reduced by ₹ 5.1 million. The aggregate amount paid for buyback was ₹ 9,302.4 million including tax and related expenses.



By Order of the Board  
For Aurobindo Pharma Limited

  
K. Nithyananda Reddy  
Vice Chairman & Managing Director  
DIN-01284195



Place: Hyderabad  
Date : February 6, 2025



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Aurobindo Pharma Limited** ("the Company"), for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

**C Manish Muralidhar**  
(Partner)  
(Membership No. 213649)  
(UDIN: 25213649BMOELZ4868)

Place: Hyderabad  
Date: February 06, 2025

(All amounts are in ₹ millions, unless otherwise stated)

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024**

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Revenue from operations</b>						
(a) Net sales/ income from operations	78,931.5	76,462.1	72,712.3	2,29,970.1	2,12,125.8	2,87,045.0
(b) Other operating income	853.7	1,498.6	805.5	3,446.0	2,091.4	2,973.7
<b>Total revenue from operations</b>	<b>79,785.2</b>	<b>77,960.7</b>	<b>73,517.8</b>	<b>2,33,416.1</b>	<b>2,14,217.2</b>	<b>2,90,018.7</b>
<b>2 Other income</b>						
(a) Foreign exchange gain (net)	-	145.8	451.7	-	530.6	387.8
(b) Others	1,572.9	1,214.2	1,173.5	4,986.4	3,829.8	5,186.0
<b>Total other income</b>	<b>1,572.9</b>	<b>1,360.0</b>	<b>1,625.2</b>	<b>4,986.4</b>	<b>4,360.4</b>	<b>5,573.8</b>
<b>Total income (1+2)</b>	<b>81,358.1</b>	<b>79,320.7</b>	<b>75,143.0</b>	<b>2,38,402.5</b>	<b>2,18,577.6</b>	<b>2,95,592.5</b>
<b>3 Expenses</b>						
(a) Cost of materials consumed	27,287.4	27,418.5	26,755.2	79,372.5	81,412.6	1,07,761.4
(b) Purchase of stock-in-trade	8,238.9	7,470.3	7,757.5	22,509.3	19,869.8	27,729.3
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,372.2)	(2,786.1)	(3,007.0)	(5,898.2)	(5,862.2)	(9,461.7)
(d) Employee benefits expense	11,315.5	11,094.8	9,896.8	33,129.8	28,966.2	39,229.4
(e) Finance costs	1,184.8	1,127.0	755.5	3,422.2	2,002.8	2,897.1
(f) Foreign exchange loss (net)	498.3	-	-	342.5	-	-
(g) Depreciation, amortisation and impairment expense	4,185.3	3,822.8	4,232.7	12,049.9	11,673.3	15,216.6
(h) Other expenses	19,037.5	19,101.8	16,102.2	56,167.5	48,271.7	66,330.3
<b>Total expenses</b>	<b>69,375.5</b>	<b>67,249.1</b>	<b>62,492.9</b>	<b>2,01,095.5</b>	<b>1,86,334.2</b>	<b>2,49,702.4</b>
<b>4 Profit before share of profit of associates and joint ventures, exceptional items and tax (1+2-3)</b>	<b>11,982.6</b>	<b>12,071.6</b>	<b>12,650.1</b>	<b>37,307.0</b>	<b>32,243.4</b>	<b>45,890.1</b>
5 Share of profit/(loss) of associates and joint ventures, net of tax	15.9	3.0	(25.9)	5.0	(45.0)	(171.6)
<b>6 Profit before exceptional items and tax (4+5)</b>	<b>11,998.5</b>	<b>12,074.6</b>	<b>12,624.2</b>	<b>37,312.0</b>	<b>32,198.4</b>	<b>45,718.5</b>
7 Exceptional items (refer note 4)	-	-	-	-	697.5	1,918.6
<b>8 Profit before tax (6-7)</b>	<b>11,998.5</b>	<b>12,074.6</b>	<b>12,624.2</b>	<b>37,312.0</b>	<b>31,500.9</b>	<b>43,799.9</b>
<b>9 Tax expense</b>						
Current tax	4,980.7	3,221.3	3,846.0	12,694.7	12,069.0	17,775.4
Deferred tax	(1,437.9)	683.8	(621.5)	(1,190.1)	(3,184.3)	(5,665.2)
<b>Total tax expense</b>	<b>3,542.8</b>	<b>3,905.1</b>	<b>3,224.5</b>	<b>11,504.6</b>	<b>8,884.7</b>	<b>12,110.2</b>
<b>10 Profit for the period (8-9)</b>	<b>8,455.7</b>	<b>8,169.5</b>	<b>9,399.7</b>	<b>25,807.4</b>	<b>22,616.2</b>	<b>31,689.7</b>
<b>11 Other comprehensive Income</b>						
A) Items that will not be reclassified subsequently to profit or loss:						
i) Re-measurement of defined employee benefit liability	(30.2)	(71.4)	(9.6)	(107.2)	(32.3)	(157.3)
ii) Equity investments through other comprehensive income – net change in fair value	9.7	46.2	27.4	57.6	7.2	20.9
iii) Income-tax relating to items that will not be reclassified to profit or loss	5.6	8.1	4.1	15.1	10.1	29.5
B) Items that will be reclassified subsequently to profit or loss:						
i) Exchange differences on translating the financial statements of foreign operations	(637.8)	2,719.9	1,865.1	1,674.1	2,112.3	1,098.5
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
<b>Total other comprehensive income/(loss) for the period (net of tax)</b>	<b>(652.7)</b>	<b>2,702.8</b>	<b>1,887.0</b>	<b>1,639.6</b>	<b>2,097.3</b>	<b>991.6</b>
<b>12 Total comprehensive income for the period (net of tax) (10+11)</b>	<b>7,803.0</b>	<b>10,872.3</b>	<b>11,286.7</b>	<b>27,447.0</b>	<b>24,713.5</b>	<b>32,681.3</b>
<b>Attributable to:</b>						
Owners of the Holding Company	7,805.4	10,876.6	11,249.9	27,463.7	24,739.5	32,721.3
Non-controlling interest	(2.4)	(4.3)	36.8	(16.7)	(26.0)	(40.0)
<b>Out of total comprehensive income above, Profit for the period attributable to:</b>						
Owners of the Holding Company	8,458.1	8,173.8	9,362.9	25,824.1	22,642.2	31,729.7
Non-controlling interest	(2.4)	(4.3)	36.8	(16.7)	(26.0)	(40.0)
<b>Other comprehensive income/(loss) attributable to:</b>						
Owners of the Holding Company	(652.7)	2,702.8	1,887.0	1,639.6	2,097.3	991.6
Non-controlling interest	-	-	-	-	-	-
<b>13 Paid-up equity share capital (face value ₹ 1 per share) (Refer note 7)</b>	<b>580.8</b>	<b>580.8</b>	<b>585.9</b>	<b>580.8</b>	<b>585.9</b>	<b>585.9</b>
<b>14 Other equity</b>						<b>2,97,842.1</b>
<b>15 Earnings per equity share (face value ₹ 1 per share)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Annualised)</b>
(a) Basic (in ₹)	14.56	14.00	16.04	44.25	38.60	54.16
(b) Diluted (in ₹)	14.56	14.00	16.04	44.25	38.60	54.16



v. — H  
\_\_\_\_\_





**NOTES:**

- 1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited consolidated financial results has been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 6, 2025. The results for the quarter and nine months ended December 31, 2024 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2024.
- 4 Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss.

Particulars	Quarter ended 31.12.2024	Quarter ended 30.09.2024	Quarter ended 31.12.2023	Nine months ended 31.12.2024	Nine months ended 31.12.2023	Year ended 31.03.2024
Loss on restructuring of business (refer note i)	-	-	-	-	(697.5)	(986.6)
Gain on settlement with customer (refer note ii)	-	-	-	-	-	1,306.0
Loss on write-off of non-current assets (refer note iii)	-	-	-	-	-	(2,238.0)
<b>Total loss</b>	-	-	-	-	(697.5)	(1,918.6)

**Note:**

- i) Accrual of severance pay and certain demolition charges on account of restructuring of business of Auro PR Inc., a step-down subsidiary of the Company.
- ii) Gain arising on account of settlement of balances with a customer by Auro PR Inc., a step-down subsidiary of the Company.
- iii) Loss arising on account of write-down of certain non-current assets held by Eugia US Manufacturing LLC, a step-down subsidiary of the Company, to its fair value less cost to sell, consequent to the sale of the assets.

- 5 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 6 During the quarter and nine months ended December 31, 2024:
- i. The Group acquired 520 equity shares (representing 52% stake) in Purple Bellflower (Pty) Limited, South Africa through its wholly owned subsidiary Aurogen South Africa (Pty) Limited. Consequent to the said acquisition, Purple Bellflower (Pty) Limited has become a wholly owned subsidiary of Aurogen South Africa (Pty) Limited.
- ii. The Group acquired 500 equity shares (representing 100% stake) in Ace Laboratories Limited, UK through its wholly owned step-down subsidiary Agile Pharma BV.
- iii. Aurex B.V. The Netherlands, merged with Aurobindo Pharma B.V, The Netherlands w.e.f. April 1, 2024.
- iv. The Parent Company acquired 590,361 (representing 49% stake) in GLS Pharma Limited, India. Consequent to the said acquisition, GLS Pharma become wholly owned subsidiary of Aurobindo Pharma Limited w.e.f October 25, 2024.
- v. The Group divested 927,237 equity shares (representing 50% stake) in Novagen Pharma (PTY) Ltd and 245 equity shares (representing 24.50% stake) in Novagen BBBEE Invest Co. (PTY) Ltd, joint ventures through its wholly owned step down subsidiary Aurogen South Africa (PTY) Ltd on October 1, 2024. Accordingly, the group has accounted ₹ 259.51 Million in other income.
- vi. TheraNym Biologics Private Limited, a wholly owned subsidiary of the Company, has allotted 2,041 equity shares (representing 2% stake) to minority shareholders w.e.f. December 11, 2024. Post allotment, TheraNym Biologics Private Limited ceased to be a wholly owned subsidiary.
- 7 The Board of Directors of the parent company at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the parent company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid up equity share capital of the parent company was reduced by ₹ 5.1 million. The aggregate amount paid for buyback was ₹ 9,302.4 million including tax and related expenses.



By Order of the Board  
For Aurobindo Pharma Limited

K.Nithyananda Reddy  
Vice Chairman & Managing Director  
DIN-01284195



Place: Hyderabad  
Date : February 6, 2025

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit / (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter and nine months ended December 31, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

M

6. We did not review the interim financial information of 22 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of ₹ 46,035.4 million and ₹ 126,485.5 million for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of ₹ 4,132.8 million and ₹ 7,290.1 million for the quarter and nine months ended December 31, 2024 respectively and total comprehensive income of ₹ 4,132.9 million and ₹ 7,278.1 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial information of 47 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ₹ 12,664.9 million and ₹ 36,648.7 million for the quarter and nine months ended December 31, 2024 respectively, total loss after tax of ₹ 693.1 million and ₹ 371.5 million for the quarter and nine months ended December 31, 2024 respectively and Total comprehensive loss of ₹ 693.1 million and ₹ 371.5 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of ₹ 15.9 million and ₹ 5.0 million for the quarter and nine months ended December 31, 2024 respectively and total comprehensive income of ₹ 15.9 million and ₹ 5.0 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement, in respect of 2 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

**C Manish Muralidhar**  
(Partner)  
Membership No. 213649  
UDIN: 25213649BMOEMA3635

Place: Hyderabad  
Date: February 06, 2025



**Annexure I to the Independent Auditor's Report on Review of Interim Unaudited Consolidated Financial Results**

The interim unaudited financial results include results of the following entities:

<b>S.No</b>	<b>Name of Component</b>	<b>Country</b>	<b>Relationship</b>
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auro Peptides Ltd	India	Direct Subsidiary
9	Apitoria Pharma Private Limited	India	Direct Subsidiary
10	Auroactive Pharma Private Limited	India	Direct Subsidiary
11	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
12	AuroZest Private Limited	India	Direct Subsidiary
13	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
14	Eugia Pharma Specialities Ltd	India	Direct Subsidiary
15	GLS Pharma Private Limited	India	Direct Subsidiary
16	TheraNyM Biologics Private Limited	India	Direct Subsidiary
17	Auro Trading Private Limited (w.e.f November 22, 2023)	India	Direct Subsidiary
18	Auro Vaccines Private Limited	India	Step-Down Subsidiary
19	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
20	Aurex B.V. (merged with Aurobindo Pharma B.V. w.e.f. April 1, 2024)	The Netherlands	Step-Down Subsidiary
21	Milpharm Limited	United Kingdom	Step-Down Subsidiary
22	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
23	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
24	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
25	Pharmacin B.V.	The Netherlands	Step-Down Subsidiary
26	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
27	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
28	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
29	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
30	Arrow Generiques SAS	France	Step-Down Subsidiary
31	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
32	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
33	Aurovitas Spain SA	Spain	Step-Down Subsidiary
34	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
35	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
36	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
37	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
38	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
39	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
40	Marel B.V.	The Netherlands	Step-Down Subsidiary
41	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
42	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
43	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
44	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
45	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
46	Eugia (UK) Limited	United Kingdom	Step-Down Subsidiary
47	Auro Pharma Inc.	Canada	Step-Down Subsidiary

JK

S.No	Name of Component	Country	Relationship
48	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
49	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
50	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
51	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
52	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
53	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
54	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
55	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
56	Aurosulud SA De CV	Mexico	Step-Down Subsidiary
57	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
58	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
59	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
60	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
61	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
62	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
63	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
64	Aurolife Pharma LLC	USA	Step-Down Subsidiary
65	Auro Health LLC	USA	Step-Down Subsidiary
66	Auro AR LLC	USA	Step-Down Subsidiary
67	Auro Vaccines LLC	USA	Step-Down Subsidiary
68	AuroLogistics LLC	USA	Step-Down Subsidiary
69	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
70	Auro Science LLC	USA	Step-Down Subsidiary
71	Auro Packaging LLC	USA	Step-Down Subsidiary
72	Vespyr Brands, LLC (Formerly known as Nurya Brands Inc)	USA	Step-Down Subsidiary
73	Eugia Inc.	USA	Step-Down Subsidiary
74	Eugia US LLC	USA	Step-Down Subsidiary
75	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
76	Eugia Steriles Private Limited	India	Step-Down Subsidiary
77	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
78	Qule Pharma Private Limited	India	Step-Down Subsidiary
79	Eugia SEZ Private Limited	India	Step-Down Subsidiary
80	Auro Pharma LLC (w.e.f July 24, 2023)	Russia	Step-Down Subsidiary
81	Purple Bellflower, South Africa (w.e.f. April 30, 2024)	South Africa	Step-Down Subsidiary
82	Ace Laboratories Limited (w.e.f. June 28, 2024)	United Kingdom	Step-Down Subsidiary
83	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
84	Raidurgam Developers Limited	India	Joint venture
85	Tergene Biotech Limited	India	Joint venture
86	Novagen Pharma (Pty) Ltd (upto October 1, 2024)	South Africa	Joint venture
87	Novagen BBBEE Invest Co (Pty) Ltd (upto October 1, 2024)	South Africa	Joint venture
88	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
89	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate

21